| Interagency Committee on Disability Research (ICDR) |
Committee, Work group, Advisory group, or Task Force |
ACF, ACL, AHRQ, ATSDR, CDC, CMS, FDA, HRSA, IHS, OS, OSG, SAMHSA |
NHLBI, NIA, NIAID, NICHD, NIDCD, NIMH, NINDS |
The ICDR's mission is to promote coordination and cooperation among federal deparments and agencies conducting disability, independent living, and rehabilitation research programs--including those that relate to assistive technology research, and research that incorporates the principles of universal design. |
| Interagency Committee on Drug Control (ICDC) |
Committee, Work group, Advisory group, or Task Force |
FDA, SAMHSA |
NIDA |
The Interagency Committee on Drug Control (ICDC) meets three times per year and is a collaboration between NIDA, DEA, FDA, ONDCP, SAMHSA, and the State Department (Chaired by Drew Townsend for 2024). Members share news on new initiates, U.S. Scheduling Actions, International Scheduling issues, upcoming Legislation initiatives, and other new business. This exchange of information and related documents are collated into minutes and circulated with the group. |
| Interagency Committee on Human Nutrition Research (ICHNR) |
Committee, Work group, Advisory group, or Task Force |
OASH, CDC, FDA |
NCI, NHLBI, OD/DPCPSI/ODS, OD/DPCPSI/ONR |
The Interagency Committee on Human Nutrition Research (ICHRN) is charged with improving the planning, coordination, and communication among federal agencies engaged in nutrition research. |
| Interagency Committee on Smoking and Health |
Committee, Work group, Advisory group, or Task Force |
CDC, OS |
NCI, NIDA |
The Committee was chartered in 1985 and advises the Secretary, Department of Health and Human Services (DHHS), the Assistant Secretary for Health, and the Centers for Disease Control and Prevention on coordination of research, educational programs, and other activities within the Department that relate to the effect of smoking on human health, and on coordination of these activities with other Federal, State, local, and private agencies. The Committee established and maintains a liaison with appropriate private entities, other Federal agencies, and State and local public agencies respecting activities relating to the effect of cigarette smoking on human health. |
| Interagency Committee on the American Community Survey (ACS) |
Committee, Work group, Advisory group, or Task Force |
ACF, AHRQ, CDC, CMS, HRSA, OS |
NICHD, OD/DPCPSI/SGMRO |
OMB in conjunction with the Census Bureau co-chairs this Federal Interagency Committee on the ACS (the Committee) established by the Interagency Committee on Statistical Policy’s Subcommittee on the ACS (ICSP-SACS). The Committee will exist to participate in reviews of the ACS content and tests of new and/or revised content for the ACS. The Committee will make recommendations on any additions, revisions, or deletions of questions on the ACS to the ICSP-SACS in its capacities of advising the Chief Statistician at OMB and the Director of the Census Bureau. |
| Interagency Comparative Genomics Working Group |
Committee, Work group, Advisory group, or Task Force |
CDC |
NCATS, NCCIH, NCI, NHGRI, NIAID, NIBIB, NICHD, NIDCR, NIGMS |
The comparative genomics program officers working group (previously animal genomics WG) was created to bridge the scientific engagement across diverse species biomedical models (NIH), agricultural models (USDA, USAID), and other non-model or research organisms (NSF, DOE) in the area of genomics. NHGRI co-leads the Inter-Agency Comparative Genomics working group with the USDA. It aims to have representatives across the government including: multiple NIH institutes, multiple divisions within the National Science Foundation, multiple USDA institutes, the United States Agency for International Development, and the Foundation for Food and Agriculture Research. |
| Interagency Coordinating Committee for Newborn Screening |
Committee, Work group, Advisory group, or Task Force |
AHRQ, CDC, FDA, HRSA |
NICHD |
This committee makes recommendations for screening certain disorders, developing a system to adjudicate newborn screening expansion, and assist states in implementing programs to test for the recommended conditions. |
| Interagency Coordinating Committee on Fetal Alcohol Spectrum Disorder (ICCFASD) |
Committee, Work group, Advisory group, or Task Force |
ACF, AHRQ, CDC, CMS, HRSA, IHS, SAMHSA |
NIAAA, NICHD, NIDA |
The Interagency Coordinating Committee on Fetal Alcohol Spectrum Disorders (ICCFASD) fosters improved communication, cooperation, and collaboration among disciplines and federal agencies that address issues related to prenatal alcohol exposure. ICCFASD is sponsored and chaired by the National Institute on Alcohol Abuse and Alcoholism (NIAAA). https://www.niaaa.nih.gov/interagency-coordinating-committee-fetal-alco… |
| Interagency Coordinating Committee on Healthy Aging and Age-Friendly Communities |
Committee, Work group, Advisory group, or Task Force |
AHRQ, ASPE, CDC, CMS, HRSA, OASH, SAMHSA |
NIA |
The Interagency Coordinating Committee on Healthy Aging and Age-Friendly Communities, authorized by the Older Americans Act, supports federal coordination on aging-related priorities. This coordination will contribute to an America that values older adults, embraces aging, and recognizes that all people have the right to live with dignity, make their own choices, and participate fully in society. |
| Interagency Coordinating Committee on Human Growth Hormone and Creutzfeldt-Jakob Disease |
Committee, Work group, Advisory group, or Task Force |
OASH, CDC, FDA |
NIDDK, NINDS |
The Public Health Service Interagency Coordinating Committee on Human Growth Hormone (hGH) and Creutzfeldt-Jakob Disease (CJD) was established in 1985 by the Assistant Secretary for Health, the Department of Health and Human Services (HHS) to review information relevant to patients who received pituitary-derived hGH that was distributed through the NIH-funded National Hormone and Pituitary Program (NHPP). The Committee analyzes this information to determine the extent of the problem of transmission of CJD (a rare, incurable brain disease) through contaminated pituitary hGH, and to inform physicians and patients who received pituitary hGH about the health risks associated with pituitary hGH. Although NHPP’s distribution of hGH ceased when its potential to transmit CJD was discovered in 1985—and today, recombinant growth hormone that is not susceptible to CJD contamination is exclusively used for treatment—the Committee continues to maintain oversight of this issue because CJD may take years or decades to develop. The Committee includes representatives from the National Institutes of Health (NIH), the Food and Drug Administration (FDA), and the Centers for Disease Control and Prevention (CDC), and is chaired by the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) Director. |